Of the 107 patients, 105 patients (98.1%) had either lung or bronchial lesions due to aspergillosis. Only 2 patients (1.9%) did not have pulmonary lesions of aspergillosis. Renal involvement of invasive aspergillosis was observed in these patients, and primary renal aspergillosis was diagnosed. Invasive aspergillosis localized to the gastrointestinal tract was not observed in our study. Of the 105 patients with invasive pulmonary aspergillosis, 12 organs were involved in 55 patients (52.4%). The distribution of organs with Aspergillus involvement is shown in table 1.
Involvement of the upper gastrointestinal tract was identified in 16 patients. The pathological findings were ulcer (in 8 patients) and abscess (in 8). Abscess was observed in the esophagus (in 3 patients) and the stomach (in 3); the site of abscess was not recorded for 2 patients. Ulcers were observed in the stomach (in 5 patients), esophagus (in 1), esophagus-cardia junction (in 1), and duodenum (in 1). Aspergillus stomatitis was not recorded in any of these patients. Eight patients were asymptomatic while they were alive. The other 8 patients had some symptoms, including upper abdominal pain (in 5 patients) and massive melena (in 4). One patient died of massive hemorrhage due to gastric ulcer. Aspergillus involvement in the upper gastrointestinal tract was not suspected in any of these cases.
Lower gastrointestinal tract involvement was identified in 9 patients. The pathological findings were ulcer (in 7 patients), abscess (in 1), and embolism (in 1). Abscesses were observed in the intestine and colon (in 1 patient). Ulcers were observed in the large intestine (in 4 patients), small intestine (in 5), and ileocecum (in 1). Rectal involvement was not noted in any of these patients. Four patients were asymptomatic. The other 5 patients had some symptoms, including bloody diarrhea (in 2 patients), a mass in the intestine and colon (in 1), panperitonitis (in 1), and ileus (in 1). Aspergillus involvement in the lower gastrointestinal tract was not suspected in any of these patients.
Our study and the study by Myoken et al. [1] have demonstrated that the gastrointestinal tract (including the oral cavity) can be a common target for invasive aspergillosis. It remains unknown whether invasive gastrointestinal aspergillosis is primary or secondary in origin. Aspergillus species may invade through the gastrointestinal tract after disruption of the intestinal mucosal barrier caused by chemotherapy [2, 3] , or they may disseminate from the lung to the gastrointestinal tract through hematogenous spread. Considering that all of the patients with gastrointestinal lesions showed pathological evidence of pulmonary aspergillosis in our study, the latter route of infection seems to be probable.
However, it should be noted that approximately one-half of the patients with gastrointestinal aspergillosis remained asymptomatic, and that the correct antemortem diagnosis of gastrointestinal aspergillosis was not established for any of these patients. These findings indicate that early diagnosis of gastrointestinal aspergillosis and prompt initiation of antiAspergillus treatment seem to be difficult unless one recognizes that invasive gastrointestinal aspergillosis is a common complication in patients undergoing cytotoxic chemotherapy for hematological malignancies. Aspergillus infection should be included in the list for differential diagnosis for gastrointestinal complications in patients with hematological malignancy.
Reply
Sir-We read with interest the letter by Kami et al. [1] about their findings regarding invasive gastrointestinal aspergillosis diagnosed after death in patients with hematological malignancy. Their comments create an opportunity to clarify some differences between oral aspergillosis and gastrointestinal aspergillosis in immunocompromised patients.
First, our clinical findings showed that invasive Aspergillus stomatitis began as a violaceous discoloration of the mucosa that rapidly progressed to a necrotic ulcer causing destruction of bone and muscle [2] , but it never developed into the gastrointestinal Aspergillus abscess described by Kami et al. [1] . Histopathologically, there was no inflammatory cell reaction identified in invasive oral aspergillosis because of the severe neutropenia that occurred while the patients underwent biopsy [2] . It appeared that the neutrophils had recovered to some extent in their patients when invasive gastrointestinal Aspergillus abscess developed.
Second, all patients with invasive Aspergillus stomatitis in our report developed primary lesions [2] , whereas all patients with gastrointestinal aspergillosis in their report had concurrent pulmonary aspergillosis, indicating the possibility of secondary gastrointestinal Aspergillus infection [1] . Other reports on gastrointestinal aspergillosis have also reported that most gastrointestinal involvement occurred in pulmonary Aspergillus infection and that isolated gastrointestinal disease was rare, which suggests that Aspergillus could disseminate from the lung to the gastrointestinal tract by hematogenous spread [3, 4] .
However, we agree with Kami et al. [1] that invasive oral and gastrointestinal aspergillosis is difficult to diagnose because mucositis secondary to cytotoxic chemotherapy may hinder prompt recognition of Aspergillus infection of the digestive tract in patients with hematological malignancy [1, 2] . Clinicians treating these patients should be aware of the facets of invasive aspergillosis as one of the oral and gastrointestinal complications during cytotoxic chemotherapy.
